You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 3
  • 260 Impact of BRCA & PD-L1 in EOC patients receiving standard 1st line therapy +/- Pembrolizumab: Exploratory analyses from the NeoPembrOV Study (GINECO)

Citation Tools

Article menu

Download PDFPDF

Ovarian cancer
260 Impact of BRCA & PD-L1 in EOC patients receiving standard 1st line therapy +/- Pembrolizumab: Exploratory analyses from the NeoPembrOV Study (GINECO)
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Le Saux O, Savoye A, Mouret-Reynier M, et al
260 Impact of BRCA & PD-L1 in EOC patients receiving standard 1st line therapy +/- Pembrolizumab: Exploratory analyses from the NeoPembrOV Study (GINECO)
International Journal of Gynecologic Cancer 2021;31:A216-A217.